"As announced last month, Graphite Bio has initiated a process to evaluate strategic alternatives that may result in changes to our business strategy," said CEO Josh Lehrer, M.D., M.Phil. "We are working expeditiously to complete this strategic review and look forward to providing an update in the future when appropriate."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRPH:
- Graphite Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
- Graphite Bio downgraded to Underperform from Neutral at BofA
- Cowen downgrades Graphite Bio on ‘uncertain strategy’ after update
- Graphite Bio downgraded to Market Perform from Outperform at Cowen
- Graphite Bio to explore strategic alternatives, cuts staff by 50%
